15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $69M | -$5M | 16.9% | -6.8% | -$1M | $9M | $11M |
| 2024 | $101M | -$480000 | 17.2% | 0.6% | $3M | $8M | $16M |
| 2023 | $84M | -$8M | 10.4% | -8.0% | -$10M | $8M | $9M |
| 2022 | $73M | -$19M | 5.6% | -23.0% | — | $9M | $10M |
| 2021 | $62M | -$33M | -3.9% | -49.0% | — | $21M | $13M |
| 2020 | $62M | -$31M | 4.4% | -45.7% | — | $21M | $49M |
| 2019 | $61M | -$34M | 4.6% | -56.3% | — | $0 | $12M |
| 2018 | $63M | -$32M | -2.5% | -51.2% | — | — | $23M |
| 2017 | $57M | -$26M | 6.5% | -45.2% | — | — | $8M |
| 2016 | — | -$20M | — | — | — | — | $17M |
| 2015 | — | -$14M | — | — | — | — | $31M |
| 2014 | — | -$21M | — | — | — | — | $66M |
| 2013 | — | -$49M | — | — | — | $20M | $12M |
| 2012 | — | -$54M | — | — | — | — | $5M |
| 2011 | — | -$21M | — | — | — | — | $6M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $17M | -$2M | 16.7% | -8.5% | -$592000 | $9M | $10M |
| Dec '25 | $18M | -$554000 | 21.1% | -2.2% | $2M | $9M | $11M |
| Sep '25 | $16M | -$2M | 14.3% | -9.9% | -$2M | $9M | $14M |
| Jun '25 | $16M | -$1M | 15.6% | -8.4% | $2M | $9M | $12M |
| Mar '25 | $19M | -$2M | 16.1% | -7.2% | -$4M | $9M | $11M |
| Dec '24 | $25M | -$756000 | 14.7% | -2.1% | $470000 | $8M | $16M |
| Sep '24 | $28M | $2M | 22.0% | 6.8% | $4M | $8M | $12M |
| Jun '24 | $26M | $343000 | 17.6% | 2.0% | $1M | $8M | $12M |
| Mar '24 | $23M | -$2M | 13.5% | -5.8% | -$3M | $8M | $7M |
| Dec '23 | $22M | -$2M | 13.0% | -2.5% | -$86000 | $8M | $9M |
| Sep '23 | $24M | -$2M | 9.3% | -7.3% | — | $9M | $8M |
| Jun '23 | $18M | -$3M | 5.7% | -16.4% | — | $9M | $9M |
| Mar '23 | $20M | -$2M | 13.2% | -7.3% | — | $9M | $11M |
| Dec '22 | $19M | -$2M | 12.1% | -10.2% | — | $9M | $10M |
| Sep '22 | $19M | -$4M | 4.2% | -19.8% | — | $14M | $13M |
| Jun '22 | $19M | -$5M | 9.3% | -24.0% | — | $16M | $31M |
| Mar '22 | $16M | -$7M | -4.9% | -41.1% | — | $18M | $10M |
| Dec '21 | $15M | -$9M | -14.6% | -54.5% | — | $21M | $13M |
| Sep '21 | $16M | -$8M | -2.1% | -43.6% | — | $21M | $23M |
| Jun '21 | $15M | -$8M | -1.7% | -51.7% | — | $21M | $32M |
How the market has priced RMTI against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, ROCKWELL MEDICAL, INC.'s revenue has grown 2.2% per year. These are computed facts, not advice.
As of FY2025, ROCKWELL MEDICAL, INC. reported $9M of total debt against $11M of cash; operating income covered interest expense -4.2×.
In FY2025, gross margin was 16.9%, operating margin -6.8%, and net margin -7.7%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.